GlaxoSmithKline (GSK) Gets a Buy from Bernstein
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
devdiscourse7d
GlaxoSmithKline's Profit Surge: A Testament to Resilience
GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...
GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
USA Today15d
Arizona says GlaxoSmithKline's greed endangered kids with asthma
The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...
pharmaphorum2d
FDA clears GSK's Priorix, first new MMR vaccine in 50 years
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
Mint4d
GlaxoSmithKline Pharmaceuticals shares hit 20% upper circuit as profit jumps fivefold in Q3FY25
Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...